Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...

Mallinckrodt PLC, the Irish pharmaceutical company with its U.S. headquarters in Hazelwood, has agreed to merge with drug maker Endo Inc. in a cash and stock transaction that values the combined ...

Endo shareholders will receive $80 million in cash and own 49.9% of the combined company. The merged firm expects $3.6 billion in 2025 revenue and $1.2 billion in adjusted EBITDA. Ready to turn ...

Endo used to manufacture and sell a long-acting opioid painkiller called Opana ER, which was withdrawn in 2017 after the U.S. FDA said its benefit did not outweigh public health risks associated ...